Pregled bibliografske jedinice broj: 790599
Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels
Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels // European journal of internal medicine, 29 (2016), 98-103 doi:10.1016/j.ejim.2015.12.014 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 790599 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels
Autori
Mikolašević, Ivana ; Zaputović, Luka ; Zibar, Lada ; Begić, Ivana ; Žutelja, Marta ; Klanac, Ana ; Majurec, Iva ; Šimundić, Tihana ; Minažek, Marija ; Orlić, Lidija
Izvornik
European journal of internal medicine (0953-6205) 29
(2016);
98-103
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
angiotensin-converting enzyme inhibitors; angiotensin II receptor type 1 blockers; kidney transplantation
Sažetak
We have analyzed effects of renin-angiotensin-aldosterone system (RAAS) inhibitors on evolution of hemoglobin (Hb) and hematocrit (Htc) levels as well as on the evaluation of kidney graft function in stable renal transplant recipients (RTRs) in respect with initially higher or lower Hb and Htc values. The study group comprised of 270 RTRs with stable graft function. Beside other prescribed antihypertensive therapy, 169 of them have been taking RAAS inhibitors We wanted to analyze the effect of the use of RAAS inhibitors on Hb and Htc in patients with initially higher or lower Hb/Htc values. For this analysis, only RTRs that were taking RAAS inhibitors were stratified into two groups: one with higher Hb and Htc (initial Hb ≥150 g/L and Htc ≥ 45%) and another one with lower Hb and Htc (initial Hb<150 g/L and Htc < 45%) values. Thirty-four RTRs with initially higher Hb and 41 RTRs with initially higher Htc had a statistically significant decrease in Hb (p=0.006) and Htc (p<0.0001) levels after 12-months of follow up. In the group of patients with initially lower Hb (135 RTRs) and Htc (128 RTRs) there was a significant increase in Hb (p=0.0001) and Htc (p=0.004) levels through the observed period. The use of RAAS inhibitors has been associated with a trend of slowing renal insufficiency in RTRs (p=0.03). RAAS inhibitors lower Hb and Htc only in RTRs with initially higher levels. In patients with initially lower Hb and Htc levels, the use of these drugs is followed by beneficial impact on erythropoiesis and kidney graft function.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Osijek,
Medicinski fakultet, Osijek,
Klinički bolnički centar Rijeka
Profili:
Ivana Mikolašević
(autor)
Ivana Begić
(autor)
Luka Zaputović
(autor)
Lidija Orlić
(autor)
Lada Zibar
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus